Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CENPE | Q02224 | 3/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 9/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.36 |
| ▸ | KMO | O15229 | 2/20 | 0.35 |
| ▸ | KIFC1 | Q9BW19 | 1/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.34 |
| ▸ | WDR5 | P61964 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5565637 | 1.00 | CENPE (0.39) | CENPEMAP4K4MINK1S1PR1S1PR3 | |
| SCHEMBL5565634 | 0.89 | GCGR (0.37) | S1PR1P2RX3 | |
| SCHEMBL5565688 | 0.88 | CENPE (0.52) | CENPES1PR1S1PR3S1PR5 | |
| SCHEMBL5565695 | 0.88 | CENPE (0.52) | CENPES1PR1S1PR3S1PR5 | |
| SCHEMBL5569162 | 0.87 | CENPE (0.36) | CENPEMAP4K4MINK1S1PR1S1PR3 | |
| SCHEMBL14421571 | 0.87 | CENPE (0.36) | CENPEMAP4K4MINK1S1PR1S1PR3 | |
| SCHEMBL4792889 | 0.86 | CENPE (0.39) | CENPEMAP4K4MINK1S1PR1S1PR3 | |
| SCHEMBL4882162 | 0.86 | CENPE (0.39) | CENPEMAP4K4MINK1S1PR1S1PR3 | |
| SCHEMBL13161714 | 0.86 | CENPE (0.54) | CENPEMAP4K4MINK1S1PR1S1PR3 | |
| SCHEMBL3462435 | 0.86 | CENPE (0.54) | CENPEMAP4K4MINK1S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070219192-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-09-20 | — | — | US | claimed |
| US-20070219192-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-09-20 | — | — | US | disclosed |
| US-20070219192-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-09-20 | — | — | US | disclosed |
| US-20070219192-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-09-20 | — | — | US | disclosed |
| WO-2007056143-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219192-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | CENPE 54/4885MAP4K4 821/4885MINK1 1912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.